<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04977544</url>
  </required_header>
  <id_info>
    <org_study_id>2019232</org_study_id>
    <nct_id>NCT04977544</nct_id>
  </id_info>
  <brief_title>Virtual Reality Exposure Therapy in the Intensive Treatment of Social Anxiety Disorder</brief_title>
  <official_title>A Randomized Controlled Study of Virtual Reality Exposure Therapy in the Intensive Treatment of Social Anxiety Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To explore the efficacy of drugs combined with virtual reality exposure therapy in the&#xD;
      treatment of phobias compared with single drug treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the level of anxiety</measure>
    <time_frame>3 months</time_frame>
    <description>the score of Hamilton anxiety scale, the minimum and maximum values are 0 and 56, and higher scores mean a worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>heart rate of the patients</measure>
    <time_frame>3 months</time_frame>
    <description>take the heart rate as a biomarker of fear, the faster heart rate means the participate is more afraid</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Phobia</condition>
  <arm_group>
    <arm_group_label>drug only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sertraline was given as a single drug, with an initial dose of 50 mg/d, and gradually increased to the maximum dose of 200 mg/d after 2 weeks. The treating physician will determine the specific dose adjustment according to the patient's condition.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vert combine with drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On the basis of sertraline drug treatment, phobia patients were given 2d/times from the 5th week, each 35-45min VR exposure treatment, 15 times as a course of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>vert</intervention_name>
    <description>On the basis of sertraline drug treatment, phobia patients were given 2d/times from the 5th week, each 35-45min VR exposure treatment, 15 times as a course of treatment.</description>
    <arm_group_label>vert combine with drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertraline</intervention_name>
    <description>Sertraline was given as a single drug, with an initial dose of 50 mg/d, and gradually increased to the maximum dose of 200 mg/d after 2 weeks. The treating physician will determine the specific dose adjustment according to the patient's condition.</description>
    <arm_group_label>drug only</arm_group_label>
    <arm_group_label>vert combine with drug</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Meet the diagnostic criteria for phobias in DSM-IV.&#xD;
&#xD;
          -  Age from 18 to 45 years old.&#xD;
&#xD;
          -  Graduated from junior high school or above.&#xD;
&#xD;
          -  No serious physical disease, no serious visual impairment, and no family history of&#xD;
             mental illness.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Exclude other psychiatric diagnosis and treatment history.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>zheng lin, doctor</last_name>
    <phone>13606509130</phone>
    <email>linzzr@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Fourth Affiliated Hospital of Zhejiang University Medical College</name>
      <address>
        <city>Yiwu</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>yunrong lu</last_name>
      <phone>13757118257</phone>
      <email>13757118257@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 20, 2021</study_first_submitted>
  <study_first_submitted_qc>July 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2021</study_first_posted>
  <last_update_submitted>July 25, 2021</last_update_submitted>
  <last_update_submitted_qc>July 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>phobia</keyword>
  <keyword>VR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety Disorders</mesh_term>
    <mesh_term>Phobia, Social</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sertraline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

